Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Wegovy sales smash forecasts after pill launch as Novo Nordisk hikes guidance
02:09am, Wednesday, 06'th May 2026
Novo Nordisk raised its outlook for 2026 after a strong performance from its newly launched Wegovy pill.
Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill
02:08am, Wednesday, 06'th May 2026
Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.
Novo Nordisk's first-quarter profit beats forecasts
01:36am, Wednesday, 06'th May 2026
Novo Nordisk , the maker of weight-loss drug Wegovy, on Wednesday reported a first-quarter adjusted operating profit above expectations.
Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026
01:31am, Wednesday, 06'th May 2026
The strong performance of Wegovy® and continued growth in International Operations have led us to raise our 2026 guidance for both adjusted sales and
Novo Nordisk: My Q1 Preview And Why I'm Doubling Down
06:56am, Tuesday, 05'th May 2026
Novo Nordisk remains a Strong Buy as it transitions to a high-volume, lower-price model, leveraging operational efficiency and AI-driven cost savings. Recent FDA approvals for Wegovy HD and Awiqli, pl
Novo Nordisk A/S - share repurchase programme
06:43am, Tuesday, 05'th May 2026
Bagsværd, Denmark, 5 May 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council
Novo Nordisk's weight-loss pill boom faces price war test
03:03am, Tuesday, 05'th May 2026
Novo Nordisk is seeing brisk early demand for its new weight-loss pill as competition with U.S. rival Eli Lilly intensifies. Investors now want proof that fast-rising prescriptions can offset a bru
3 Absurdly Cheap Growth Stocks to Buy in May 2026
05:22pm, Monday, 04'th May 2026
These stocks have been struggling over the past year, but their growth days are far from over.
Novo Nordisk's Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance
02:04pm, Monday, 04'th May 2026
Novo Nordisk's Wegovy pill has created another boom in the GLP-1 drug market. Eli Lilly recently introduced its Foundayo pill for weight loss, three months after the launch of its rival's drug.
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
01:10pm, Monday, 04'th May 2026
NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.
Novo Nordisk: A Generational Buying Opportunity Ahead Of Q1 Earnings
08:33am, Monday, 04'th May 2026
Novo Nordisk is reiterated as a 'buy' ahead of Q1 2026 earnings, with expectations for a narrative inflection and potential upside over 40%. NVO's aggressive pricing strategy, including a 50% Wegovy p
NVO DCF Analysis: Intrinsic Value $88 vs Price $44
07:28am, Monday, 04'th May 2026
On May 04, 2026, we present a detailed DCF analysis for Novo Nordisk AS (NVO). The company has experienced notable price performance with a 1-week increase of 6
'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds
06:45am, Monday, 04'th May 2026
For the first time in 16 years, oncology is no longer the largest contributor to late-stage pipeline value, Deloitte has found. Pharma R&D returns for the world's top 20 pharma companies have improved
Weekend Morning Brew: Big Tech AI Capex Surges as Oil Spikes
07:36am, Saturday, 02'nd May 2026
Weekly Market HighlightsWeekly breadth was moderately positive with 4,963 advancers versus 4,504 decliners, including 918 stocks up more than 10% and 855 stock
Canada approves second generic version of Ozempic
03:50pm, Friday, 01'st May 2026
The Canadian health regulator said on Friday that it had approved Canada-based Apotex's generic version of semaglutide, making it the second copycat version of Danish
